OR WAIT null SECS
July 02, 2024
A cross-sectional study evaluates the difference in clinical outcomes and demographics between pediatric RSV patients during these multiple timeframes.
June 28, 2024
A cross-sectional audit study determines how racial and ethnic disparities—among English, Mandarin, and Spanish-speaking patients—can impact access.
June 27, 2024
A longitudinal observational study examined whether the program was related to access to hospital-based services, while determining if that association differs by hospital ownership.
June 26, 2024
A retrospective study investigates whether use of these portals can be defined by clinical and sociodemographic data.
June 25, 2024
The Hopewell facility—which will serve as the CDMO’s North American hub—is expected to help accelerate the cell and gene therapy delivery process.
June 24, 2024
In an interview with Pharma Commerce Editor Nicholas Saraceno, Fran Gregory, PharmD, Vice President of Emerging Therapies, Cardinal Health, discusses ways that changes made to reimbursement models are affecting patient therapies in the biosimilar space.
June 12, 2024
A retrospective cohort study investigates the characteristics of female patients with localized breast cancer that are associated with this nonpersistence.
June 10, 2024
A cohort study explores the connection between the rise in Medicare Advantage plan coverage and enrollee satisfaction.
June 07, 2024
By marrying real-world evidence and AI, pharma stakeholders can identify new opportunities to tailor interventions in a way that is most impactful to patients—helping them overcome roadblocks in initiating and maintaining therapy.
Companies need to alter their thinking to better prioritize patients. Here are three simple yet impactful engagement elements that could help.